PI	10
MPR 0	g 2000
The state of the s	*11 inder the Par

Signature



PTO/SR/30 (5/2000)

Approved for use through xx/xx/xxxx. OutP.0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number Application Number REQUEST Filing Date **CONTINUED EXAMINATION (RCE)** First Named Inventor TRANSMITTAL Group Art Unit Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, **Examiner Name** provides for continued examination of an utility or plant application filed on or after June 8, 1995. Attorney Docket Number See The American Inventors Protection Act of 1999 (AIPA). This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application. 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (d) (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office 47 (Apr. 11, 2000), which established RCE practice. Submission required under 37 C.F.R. § 1.114 Previously submitted Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on _ (Any unentered amendment(s) referred to above will be entered). Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____ iii. Other **Enclosed** Amendment/Reply Affidavit(s)/Declaration(s) Information Disclosure Statement (IDS) TRELIMINARY AMENDMENT AND REMARKS iv. X Other 2. Miscellaneous Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period of ______ months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(i) required) b. Other 3. Fees The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed. The Director is hereby authorized to charge the following fees, or credit any overpayments, to RCE fee required under 37 C.F.R. § 1.17(e) 04/10/2001 CCHAU1 00000155 09271024 Extension of time fee (37 C.F.R. §§ 1.136 and 1.17) 355.00 OP 01 FC:279 iii.] | Other Check in the amount of \$__355.00 enclosed Payment by credit card (Form PTO-2038 enclosed) SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED Registration No. (Attorney/Agent) (Print /Type) Name Signature Date CERTIFICATE OR MAILING OR TRANSMISSION I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on: Name (Print/Type)

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Commissioner for Patents, Box RCE, Washington, DC 20231.

Date



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Asgeir Saebo et al.

Serial No.:

09/271,024

03/17/99

Group Art Unit: 1617 Examiner:

Wang, S.

Filed: Entitled:

CONJUGATED LINOLEIC ACID COMPOSITIONS

AMENDMENT TRANSMITTAL

BOX NON FEE AMENDMENT

Assistant Commissioner for Patents Washington, D.C. 20231

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)(1)(i)(A)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231

Dated: April 4, 2001

Sir or Madam:

Transmitted herewith is an amendment for this application. The fee has been calculated as shown below.

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE	ADDITIONAL FEE
Total Claims	9	_	20	0	×	18.00	\$0.00
Independent Claims	2	_	3	0	×	80.00	\$0.00

TOTAL DUE

0.00

- No additional fee is required. 1.
- Please charge any additional fees, including any fees necessary for extensions of time, or credit overpayment to 2. Deposit Account No. 08-1290. An originally executed duplicate of this transmittal is enclosed for this purpose.

Dated: April 4, 2001

Registration No. 44,174

MEDLEN & CARROLL, LLP 220 Montgomery Street, Suite 2200 San Francisco, California 94104

(415) 705-8410

PATENT

Attorney Docket No. CONLINCO-03681

Group No.: 16

IN THE UNITED STATES PATENT AND TRADEMARK OFF

In re Application of: Asgeir Saebo et al.

Serial No.:

09/271,024

Filed:

03/17/99

Entitled:

Examiner: CONJUGATED LINOLEIC ACID COMPOSITIONS

PRELIMINARY AMENDMENT AND REMARKS

Box RCE Assistant Commissioner for Patents Washington, D.C. 20231

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)(1)(i)(A)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Dated: April 4, 2001

Sir or Madam:

The following communication is responsive to the final Office Action mailed January 9, 2001. The Applicants respectfully request reconsideration of the application in view of the following remarks.

台

AMENDMENTS

Please enter the following amendments in the above-referenced application.

IN THE SPECIFICATION:

On page 7, please replace the first full paragraph with the following rewritten paragraph, in accordance with 37 CFR 1.121(b)(1)(i-ii).

In some embodiments, the low impurity CLA described above may be provided as acylglycerols or alkylesters. Accordingly, in some embodiments, an acylglycerol composition is provided which comprises a plurality of acylglycerol molecules wherein the acylglycerol

